Literature DB >> 12483218

Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice.

Stephan G Anagnostaras1, Geoffrey G Murphy, Susan E Hamilton, Scott L Mitchell, Nancy P Rahnama, Neil M Nathanson, Alcino J Silva.   

Abstract

Blockade of cholinergic neurotransmission by muscarinic receptor antagonists produces profound deficits in attention and memory. However, the antagonists used in previous studies bind to more than one of the five muscarinic receptor subtypes. Here we examined memory in mice with a null mutation of the gene coding the M1 receptor, the most densely distributed muscarinic receptor in the hippocampus and forebrain. In contrast with previous studies using nonselective pharmacological antagonists, the M1 receptor deletion produced a selective phenotype that included both enhancements and deficits in memory. Long-term potentiation (LTP) in response to theta burst stimulation in the hippocampus was also reduced in mutant mice. M1 null mutant mice showed normal or enhanced memory for tasks that involved matching-to-sample problems, but they were severely impaired in non-matching-to-sample working memory as well as consolidation. Our results suggest that the M1 receptor is specifically involved in memory processes for which the cortex and hippocampus interact.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12483218     DOI: 10.1038/nn992

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  168 in total

1.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity.

Authors:  Cyrille Sur; Pierre J Mallorga; Marion Wittmann; Marlene A Jacobson; Danette Pascarella; Jacinta B Williams; Philip E Brandish; Douglas J Pettibone; Edward M Scolnick; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

2.  Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Authors:  Jelveh Lameh; Krista McFarland; Jorgen Ohlsson; Fredrik Ek; Fabrice Piu; Ethan S Burstein; Ali Tabatabaei; Roger Olsson; Stefania Risso Bradley; Douglas W Bonhaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-15       Impact factor: 3.000

3.  Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Authors:  Zixiu Xiang; Analisa D Thompson; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2011-12-01       Impact factor: 4.030

4.  M2 muscarinic acetylcholine receptors regulate long-term potentiation at hippocampal CA3 pyramidal cell synapses in an input-specific fashion.

Authors:  Fang Zheng; Jürgen Wess; Christian Alzheimer
Journal:  J Neurophysiol       Date:  2012-04-04       Impact factor: 2.714

5.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Authors:  Evan P Lebois; Thomas M Bridges; L Michelle Lewis; Eric S Dawson; Alexander S Kane; Zixiu Xiang; Satyawan B Jadhav; Huiyong Yin; J Phillip Kennedy; Jens Meiler; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

Review 6.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 7.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

8.  The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner.

Authors:  Benoit Poulin; Adrian Butcher; Phillip McWilliams; Julie-Myrtille Bourgognon; Robert Pawlak; Kok Choi Kong; Andrew Bottrill; Sharad Mistry; Jürgen Wess; Elizabeth M Rosethorne; Steven J Charlton; Andrew B Tobin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

Review 9.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

10.  Inactivation of JAK2/STAT3 signaling axis and downregulation of M1 mAChR cause cognitive impairment in klotho mutant mice, a genetic model of aging.

Authors:  Seok-Joo Park; Eun-Joo Shin; Sun Seek Min; Jihua An; Zhengyi Li; Yoon Hee Chung; Ji Hoon Jeong; Jae-Hyung Bach; Seung-Yeol Nah; Won-Ki Kim; Choon-Gon Jang; Yong-Sun Kim; Yo-Ichi Nabeshima; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neuropsychopharmacology       Date:  2013-02-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.